Mild Cognitive Impairment Clinical Trial
Official title:
The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment (Kodro Solution)
This is a pilot study to examine the feasibility of a formal 30-minute daily program on a
tablet computer (simply a "tablet") in subjects with mild cognitive impairment (MCI). The
purpose of the program, known as Kodro Solution, is to increase physical activity, maintain
social interaction, improve nutrition and exercise cognitive skills using a tablet. In
addition to feasibility, outcome measures will include: (a) health-related quality of life,
(b) self-esteem, (c) activities of daily living, (d) socialization, (e) mood, and (f)
cognition. Study participants must have a study partner who can assist them with training on
use of the tablet and the Kodro Solution program.
Fifty (50) study subjects and their study partners will be recruited at the Wien Center. A
delayed start design will be utilized. Study subjects will be randomly assigned to either
active treatment (Kodro+) or delayed treatment (Kodro+D). Active treatment with Kodro
Solution will be initiated at the baseline visit for Kodro+ subjects and 12 weeks after
baseline for Kodro+D subjects. The 12-week period without tablets will serve as a control.
Active treatment with Kodro Solution will continue for 36 weeks for the Kodro+ subjects and
24 weeks for the Kodro+D subjects. For both groups, the outcome measures will be assessed at
baseline, week 12 and week 36. The lagged design will facilitate enrollment and enable the
assessment of a dose effect.
Background: Due to increased longevity and aging of the baby boomer, the number of older
persons with cognitive disorders such as Alzheimer's Disease (AD) is increasing rapidly. It
is uncertain whether cognitive and memory training intervention programs can delay the onset
or reduce the risk for the subsequent development of AD, but several studies have shown that
cognitive training in people with Mild Cognitive Impairment (MCI) has a moderate effect on
memory.
A tablet-based platform known as Kodro was developed in 2011 by a French company to improve
multiple domains, including memory and quality of life, among older persons with and without
memory disorders. The goals of the program are to increase physical activity, maintain
social interaction, improve nutrition and exercise cognitive skills. The program requires
internet access to enable connection with the program, family and friends, other Kodro users
and external experts. The version of Kodro in this study, Kodro Solution, was designed for
seniors with mild cognitive impairment or very mild dementia, who are living at home. Kodro
Solution is customized to each user's interests and hobbies. For example, a user with an
interest in cuisine might be presented with a brief video about the top toppings for
hamburgers; this user would then be asked 5 questions to test his/her memory.
Purpose: To determine whether Kodro solution is feasible among older people with MCI. The
secondary aim is to measure the effect of Kodro on cognition, mood, activities of daily
living and quality of life.
Procedures Subjects: Potential subjects will be selected from patients diagnosed with MCI at
the Wien Center who are at least 60 years of age. Subjects will be required to have a
wireless connection to the internet and a study partner. The subject should be capable of
learning to use the tablet and Kodro system with minimal assistance from the study partner
(friend or family member). The role of the study partner is to assist the staff with the
assessment of the subject and to assist the subject with study visits and the use of Kodro.
Baseline Visit and Randomization: After a subject has been consented and deemed eligible for
the study, he/she will be randomized to either a group with Kodro at baseline ("Kodro+") or
a group with Kodro delayed until 12 weeks post-baseline ("Kodro+D"). Study raters will be
blind to subject's randomization.
Intervention: Subjects in the Kodro+ group will be trained on the use of the tablet and
Kodro at the baseline visit, and will continue using Kodro for 36 weeks. Subjects in the
Kodro+D group will be trained on the tablet and Kodro at 12 weeks, and will continue to use
Kodro for 24 weeks. Participants will be expected to log in and utilize the program for a
minimum of 30 minutes daily. The participants will perform various activities such as
reading newspaper articles, books, listening to audio tapes, watching video clips, and
playing games. Information regarding the participant's usage of the program and how well
they perform on the activities is stored on Kodro's secure server. The program is customized
to the user's level and the information obtained will gauge the level of difficulty as well
as appropriateness of activities that are offered daily to the participant.
Assessments: The subjects' use of Kodro will be collected continuously throughout the study
via a secure server in France. There will not be any identifying information collected such
as name, address, etc. The data collected will include frequency of use, diversity of
activities and scores on activities.
Assessments of cognition, mood, activities of daily living and quality of life will be done
at the baseline visit, 12-week visit and the final 36-week visit.
Statistical Analysis The main outcome measure will be the drop-out rate and use of Kodro.
The secondary outcome measures will be scores on tests of cognition, mood, quality of life
and activities of daily living.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |